Your browser is no longer supported. Please, upgrade your browser.
Settings
ALKS Alkermes plc daily Stock Chart
ALKS [NASD]
Alkermes plc
Index- P/E- EPS (ttm)-0.76 Insider Own0.60% Shs Outstand160.87M Perf Week-15.47%
Market Cap5.31B Forward P/E62.74 EPS next Y0.53 Insider Trans-13.67% Shs Float153.97M Perf Month-20.52%
Income-117.90M PEG- EPS next Q-0.04 Inst Own- Short Float4.67% Perf Quarter-24.59%
Sales1.05B P/S5.04 EPS this Y35.30% Inst Trans0.44% Short Ratio9.34 Perf Half Y-30.79%
Book/sh7.41 P/B4.45 EPS next Y128.70% ROA-7.90% Target Price49.18 Perf Year-32.89%
Cash/sh2.90 P/C11.37 EPS next 5Y64.59% ROE-11.90% 52W Range32.77 - 71.22 Perf YTD-39.70%
Dividend- P/FCF1061.74 EPS past 5Y-47.10% ROI-9.50% 52W High-52.13% Beta1.52
Dividend %- Quick Ratio2.60 Sales past 5Y9.40% Gross Margin84.30% 52W Low4.03% ATR2.07
Employees2000 Current Ratio2.90 Sales Q/Q14.40% Oper. Margin-8.90% RSI (14)33.53 Volatility5.68% 5.71%
OptionableYes Debt/Eq0.24 EPS Q/Q6.10% Profit Margin-13.20% Rel Volume1.27 Prev Close33.00
ShortableYes LT Debt/Eq0.24 EarningsOct 23 BMO Payout- Avg Volume769.55K Price34.09
Recom2.50 SMA20-12.26% SMA50-16.12% SMA200-27.20% Volume976,311 Change3.30%
Nov-05-18Initiated Piper Jaffray Neutral $40
Aug-07-18Initiated Stifel Hold $15 → $45
Jun-21-18Downgrade Morgan Stanley Equal-Weight → Underweight
Jun-06-18Initiated B. Riley FBR, Inc. Buy $60
May-16-18Upgrade Citigroup Neutral → Buy
May-11-18Initiated BofA/Merrill Buy $56
Apr-02-18Downgrade Evercore ISI Outperform → In-line
Feb-22-18Downgrade Jefferies Buy → Hold
Oct-16-17Downgrade Barclays Overweight → Equal Weight $66 → $50
Jun-13-17Downgrade Leerink Partners Outperform → Mkt Perform
Oct-21-16Upgrade JP Morgan Neutral → Overweight
Oct-21-16Reiterated Leerink Partners Outperform $57 → $70
Oct-21-16Reiterated Jefferies Buy $62 → $70
Oct-04-16Resumed Leerink Partners Outperform $57
Jan-21-16Reiterated Leerink Partners Outperform $84 → $58
Jan-21-16Downgrade Morgan Stanley Overweight → Underweight
Jan-21-16Downgrade JP Morgan Overweight → Neutral
Oct-07-15Reiterated Barclays Overweight $77 → $79
Sep-01-15Upgrade Morgan Stanley Underweight → Overweight
Jun-09-15Initiated Guggenheim Neutral
Nov-15-18 04:13PM  EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against Alkermes plc ALKS Business Wire
Nov-12-18 01:00AM  Just How Bad Is Alkermes' Depression Drug Setback? Motley Fool -7.88%
Nov-09-18 11:09AM  Alkermes Losses Alert: Bernstein Liebhard LLP Announces First Investigation Of Alkermes plc - ALKS PR Newswire
07:32AM  The Daily Biotech Pulse: SITC Presentations Pick Up Pace, Sandoz' Voluntary Recall Benzinga
Nov-08-18 04:55PM  Why Alkermes' Depression Drug Stumbled, and How Illumina Plans to Profit From M&A Motley Fool
Nov-06-18 04:01PM  Alkermes' Corporate Presentation to be Webcast at Upcoming Healthcare Conferences PR Newswire
08:01AM  Alkermes Presents New Data on ALKS 4230 at Society for Immunotherapy of Cancer's (SITC) 33rd Annual Meeting PR Newswire
Nov-02-18 03:32PM  Is Alkermes plc (NASDAQ:ALKS) Overpaying Its CEO? Simply Wall St. -7.57%
10:16AM  FDA Committees' Unfavorable Ruling Depresses Alkermes Shares Benzinga
08:01AM  The Daily Biotech Pulse: Illumina Snaps Up Pacific Bioscience, Thumbs Down For Alkermes Depressive Disorder Drug Benzinga
Nov-01-18 06:57PM  Alkermes stock falls after FDA committee votes against depression drug MarketWatch
06:25PM  Alkermes' depression treatment fails to get FDA panel backing Reuters
06:24PM  Alkermes Reports on Outcome of FDA Advisory Committee Meeting on ALKS 5461 for the Adjunctive Treatment of Major Depressive Disorder PR Newswire
05:15PM  Alkermes depression drug in peril after FDA advisory vote American City Business Journals
05:05PM  FDA panel votes against Alkermes' depression treatment Reuters
02:03PM  Alkermes depression drug facing FDA panel, here's what to... CNBC Videos
09:05AM  Alkermes stock halted as FDA committee considers depression drug MarketWatch
07:00AM  Trading in Alkermes Ordinary Shares Halted Today PR Newswire
Oct-31-18 08:45AM  New Research: Key Drivers of Growth for Alkermes plc, PulteGroup, Las Vegas Sands, Barrick Gold, Avangrid, and Fomento Economico Mexicano S.A.B. de C.V Factors of Influence, Major Initiatives and Sustained Production GlobeNewswire
Oct-30-18 09:01AM  Alkermes stock drops 6.5% after FDA briefing documents raise questions about depression drug MarketWatch
Oct-29-18 01:58PM  FDA set to review new drugs aimed at fighting depression CNBC Videos
01:13PM  Alkermes Announces Publication of Phase 3 Data for ALKS 5461 for Adjunctive Treatment of Major Depressive Disorder in Molecular Psychiatry PR Newswire
01:10PM  Benzinga's Week Ahead: Can Facebook, Apple Earnings Rescue The Stock Market? Benzinga
Oct-26-18 07:00AM  Alkermes Announces Recipients of 3rd Annual ALKERMES INSPIRATION GRANTS® PR Newswire
Oct-24-18 01:46PM  Alkermes Makes Financial Progress as Its Pipeline Moves Forward Motley Fool
08:00AM  Today's Research Reports on Trending Tickers: Alkermes and Amarin ACCESSWIRE
Oct-23-18 09:45PM  Edited Transcript of ALKS earnings conference call or presentation 23-Oct-18 12:30pm GMT Thomson Reuters StreetEvents
01:18PM  Alkermes PLC (ALKS) Q3 2018 Earnings Conference Call Transcript Motley Fool
11:09AM  Alkermes (ALKS) Exceeds Q3 Earnings Estimates, Raises Outlook Zacks
08:25AM  Alkermes (ALKS) Beats Q3 Earnings and Revenue Estimates Zacks
07:20AM  Alkermes: 3Q Earnings Snapshot Associated Press
07:00AM  Alkermes Plc Reports Third Quarter 2018 Financial Results PR Newswire
Oct-22-18 02:41PM  Alkermes Q3 Earnings Preview Benzinga
10:32AM  BIIB, ALKS Q3 Earnings Due on Oct 23: What's in Store? Zacks
Oct-21-18 05:15PM  The Week Ahead In Biotech: ESMO Conference, PDUFA Dates, Clinical Trial Results, Large-Cap Pharma Earnings And IPOs Benzinga
Oct-19-18 09:38AM  Alkermes Boasts Strong Portfolio and Impressive Pipeline Zacks
Oct-18-18 09:30AM  EBS or ALKS: Which Is the Better Value Stock Right Now? Zacks
Oct-17-18 07:00AM  Alkermes Highlights Ongoing Commitment to Research and Innovation in Depression and Schizophrenia at 2018 Psych Congress PR Newswire
Oct-16-18 04:01PM  Alkermes to Host Conference Call to Discuss Third Quarter 2018 Financial Results PR Newswire
Sep-27-18 07:50AM  Consolidated Research: 2018 Summary Expectations for Pan American Silver, Invesco, Diodes, INVESCO MORTGAGE CAPITAL INC, Alkermes plc, and Golar LNG Partners LP Fundamental Analysis, Key Performance Indications GlobeNewswire
Sep-26-18 10:09AM  Opioid legislation could lift certain hospital operators, drugmakers MarketWatch
Sep-19-18 08:51AM  Are Options Traders Betting on a Big Move in Alkermes (ALKS) Stock? Zacks
Sep-12-18 02:14PM  Why Alkermes plc (NASDAQ:ALKS) Is A Financially Healthy Company Simply Wall St.
Sep-11-18 09:37AM  Alkermes Expands Study to Evaluate ALKS 4230-Keytruda Combo Zacks
Sep-10-18 07:00AM  Alkermes Initiates Clinical Evaluation of Novel Immuno-Oncology Drug Candidate ALKS 4230 in Combination With PD-1 Inhibitor Pembrolizumab PR Newswire
Sep-05-18 07:00AM  Alkermes Announces 3rd Annual Competitive Grants Program to Support Those Affected by Mental Health and Substance Use Disorders PR Newswire
Aug-24-18 02:00PM  3 Biotech Stocks That May Rise as Much as 16% Investopedia
Aug-08-18 06:13AM  Alkermes settles gender bias lawsuits for undisclosed amounts American City Business Journals
Aug-07-18 09:30AM  ANIK vs. ALKS: Which Stock Is the Better Value Option? Zacks
Aug-01-18 04:00PM  Alkermes' Corporate Presentation to be Webcast at the 38th Annual Canaccord Genuity Growth Conference PR Newswire
Jul-27-18 11:53AM  Collaborations Help Alkermes Flip to Profitability Motley Fool
Jul-26-18 09:24PM  Edited Transcript of ALKS earnings conference call or presentation 26-Jul-18 12:30pm GMT Thomson Reuters StreetEvents
08:53AM  Alkermes: 2Q Earnings Snapshot Associated Press
07:00AM  Alkermes Plc Reports Second Quarter 2018 Financial Results PR Newswire
Jul-25-18 02:33PM  Earnings Preview: Alkermes Benzinga
Jul-19-18 04:00PM  Alkermes to Host Conference Call to Discuss Second Quarter 2018 Financial Results PR Newswire
Jul-05-18 12:25PM  A Look At Biotech In 2018 And The Biggest Catalysts Coming Up In The Second Half Of The Year Benzinga
Jul-03-18 03:27PM  Alkermes' Aristada Initio Approved by FDA for Schizophrenia Zacks
09:25AM  Company News For Jul 3, 2018 Zacks
Jul-02-18 09:10AM  Benzinga Pro's 5 Stocks To Watch Today Benzinga
07:01AM  FDA Approves ARISTADA INITIO for the Initiation of ARISTADA® for Schizophrenia PR Newswire
Jun-24-18 10:43AM  The Week Ahead In Biotech: Conferences, Clinical Trials And IPOs Benzinga
Jun-21-18 05:46PM  Why Alkermes Tumbled 15% Today Motley Fool -15.01%
04:38PM  Why Stamps.com, iQiyi, and Alkermes Slumped Today Motley Fool
11:19AM  Drugs from Heron Therapeutics and two other biotech companies can boost your investment returns by reducing opioid abuse MarketWatch
Jun-19-18 07:05AM  Breakfast Technical Briefing on Alkermes and Three Other Additional Biotech Stocks ACCESSWIRE
Jun-08-18 07:20AM  Wired News Alkermes Gets License Payment from Biogen Following Review of Preliminary Gastrointestinal Tolerability Data of BIIB098 for Multiple Sclerosis Treatment ACCESSWIRE
Jun-06-18 04:00PM  Alkermes to Present at Goldman Sachs 39th Annual Global Healthcare Conference PR Newswire
08:53AM  Benzinga Pro's 5 Stocks To Watch Today Benzinga
08:42AM  Alkermes plc (NASDAQ:ALKS): Is Breakeven Near? Simply Wall St.
07:00AM  Alkermes Receives $50 Million Payment From Biogen Following Review of Preliminary Gastrointestinal Tolerability Data From the Ongoing BIIB098 Clinical Development Program PR Newswire
Jun-04-18 07:45AM  Detailed Research: Economic Perspectives on Bank of Nova Scotia, Eaton Corporation, Canadian National Railway, MakeMyTrip, Altisource Portfolio Solutions S.A., and Alkermes plc What Drives Growth in Today's Competitive Landscape GlobeNewswire
May-29-18 04:00PM  Alkermes' Corporate Presentation to be Webcast at the Jefferies 2018 Healthcare Conference PR Newswire
May-23-18 07:00AM  Alkermes to Present Data on Depression and Schizophrenia Portfolios at Upcoming American Society of Clinical Psychopharmacology Annual Meeting PR Newswire
May-14-18 04:01PM  Alkermes' Corporate Presentation to be Webcast at the UBS Global Healthcare Conference PR Newswire
May-11-18 08:21AM  The Zacks Analyst Blog Highlights: Seagate, Grafton, Ingersoll-Rand and Alkermes Zacks
May-10-18 04:01PM  Alkermes' Corporate Presentation to be Webcast at the Bank of America Merrill Lynch Health Care Conference PR Newswire
12:35PM  4 Top Stocks to Buy as Irish Economy Gathers Steam InvestorPlace
09:05AM  4 Top Stocks to Buy As Irish Economy Gathers Steam Zacks
May-04-18 07:00AM  Alkermes Launches Award Program To Support And Advance Central Nervous System Disorders Research PR Newswire
May-03-18 04:00PM  Alkermes to Host Webcast and Conference Call to Discuss ALKS 3831 Development Program PR Newswire
May-02-18 04:00PM  Alkermes' Corporate Presentation to be Webcast at the Deutsche Bank 43rd Annual Health Care Conference PR Newswire
Apr-30-18 07:00AM  Alkermes to Present Clinical Data at Upcoming American Psychiatric Association Annual Meeting PR Newswire
Apr-27-18 01:19PM  Alkermes (ALKS) Q1 2018 Earnings Conference Call Transcript Motley Fool
11:53AM  Alkermes (ALKS) Reports Wider-Than-Expected Loss in Q1 Zacks
Apr-26-18 11:29PM  Edited Transcript of ALKS earnings conference call or presentation 26-Apr-18 12:30pm GMT Thomson Reuters StreetEvents
03:22PM  After a Bumpy Ride, Alkermes Confirms That It's Back on Track Motley Fool
12:58PM  What Are Analysts Saying About Alkermes plcs (NASDAQ:ALKS) Earnings Outlook? Simply Wall St.
10:30AM  BioMarin (BMRN) Q1 Earnings Lower Than Expected, Sales Beat Zacks
08:44AM  Alkermes: 1Q Earnings Snapshot Associated Press
07:05AM  Alkermes Plc to Host Earnings Call ACCESSWIRE
07:01AM  Alkermes Completes Patient Enrollment in Pivotal Weight Study of ALKS 3831 for Schizophrenia PR Newswire
07:00AM  Alkermes Plc Reports First Quarter 2018 Financial Results PR Newswire
Apr-23-18 11:16AM  Is Alkermes' Promising Depression Drug Back On Track? Motley Fool
Apr-22-18 10:50AM  Johnson & Johnson's First-Quarter 2018 Earnings Review Motley Fool
Apr-19-18 04:00PM  Alkermes to Host Conference Call to Discuss First Quarter 2018 Financial Results PR Newswire
Apr-18-18 10:07AM  Biotech Stock Roundup: ALKS Up, CLDX Down, ALXN to Acquire Wilson Therapeutics Zacks
07:30AM  Wired News FDA Accepts NDA Review for Alkermes ALKS 5461 for Treatment of Major Depressive Disorder ACCESSWIRE
Apr-17-18 06:33PM  Alkermes Rallies as FDA Accepts NDA for Depression Drug Zacks
08:45AM  Company News For Apr 17, 2018 Zacks
Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in various therapeutic areas in the United States, Ireland, and internationally. The company's marketed products include ARISTADA (aripiprazole lauroxil), an extended-release intramuscular injectable suspension for the treatment of schizophrenia; VIVITROL (naltrexone for extended-release injectable suspension) for the treatment of alcohol and opioid dependence; INVEGA SUSTENNA for the treatment of schizophrenia and schizoaffective disorder; XEPLION, INVEGA TRINZA, and TREVICTA for treating schizophrenia; RISPERDAL CONSTA for the treatment of schizophrenia and bipolar I disorder; AMPYRA (dalfampridine)/FAMPYRA (fampridine) to enhance walking in adults with multiple sclerosis (MS) who have walking disability; and BYDUREON (exenatide extended-release for injectable suspension) and BYDUREON BCise for the treatment of type 2 diabetes. It is also developing Aripiprazole Lauroxil NanoCrystal Dispersion; ALKS 5461 for the treatment of depressive disorder; ALKS 3831 to treat schizophrenia; BIIB098, a monomethyl fumarate, which is in Phase III clinical trials to treat relapsing forms of MS; and ALKS 4230, an engineered fusion protein that is in Phase I clinical trials for cancer immunotherapy. The company has collaboration agreements with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International; development and license agreement with AstraZeneca plc; and license and collaboration agreement with Biogen MA Inc. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MITCHELL PAUL JDirectorNov 02Option Exercise8.981,0008,9801,000Nov 02 05:22 PM
MITCHELL PAUL JDirectorNov 02Sale37.511,00037,5100Nov 02 05:22 PM
MITCHELL PAUL JDirectorOct 01Option Exercise8.981,0008,9801,000Oct 02 07:52 PM
MITCHELL PAUL JDirectorOct 01Sale42.421,00042,4200Oct 02 07:52 PM
MITCHELL PAUL JDirectorSep 04Option Exercise8.981,0008,9801,000Sep 05 04:22 PM
MITCHELL PAUL JDirectorSep 04Sale44.581,00044,5800Sep 05 04:22 PM
MITCHELL PAUL JDirectorAug 01Option Exercise8.981,0008,9801,000Aug 03 04:26 PM
MITCHELL PAUL JDirectorAug 01Sale43.681,00043,6800Aug 03 04:26 PM
BLOOM FLOYD EDirectorJul 16Sale43.9520,000879,024127,923Jul 18 07:51 PM
MITCHELL PAUL JDirectorJul 03Option Exercise8.981,0008,9801,000Jul 03 05:08 PM
MITCHELL PAUL JDirectorJul 03Sale41.861,00041,8600Jul 03 05:08 PM
FRATES JAMES MSVP, Alks Inc; CFO ALKSJun 12Sale50.0016,842842,17937,234Jun 13 08:26 PM
Hopkinson Craig C.SVP, Med Dev/Med Affairs, CMOJun 07Option Exercise0.001,25001,250Jun 08 05:31 PM
MITCHELL PAUL JDirectorJun 01Option Exercise8.981,0008,9801,000Jun 04 05:18 PM
MITCHELL PAUL JDirectorJun 01Sale47.341,00047,3400Jun 04 05:18 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.May 24Option Exercise12.2920,000245,800192,644May 24 05:24 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.May 24Sale45.2220,000904,424172,644May 24 05:24 PM
POPS RICHARD FDirector and CEO, Alkermes plcMay 22Option Exercise12.2920,000245,800686,352May 24 05:18 PM
POPS RICHARD FDirector and CEO, Alkermes plcMay 22Sale45.4620,000909,163666,352May 24 05:18 PM
Gaffin David JosephSVP, CLO, Alkermes, Inc.May 18Option Exercise12.292753,38036,638May 21 06:25 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.May 17Option Exercise12.2920,000245,800192,644May 17 07:01 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.May 17Sale46.1420,000922,846172,644May 17 07:01 PM
POPS RICHARD FDirector and CEO, Alkermes plcMay 15Option Exercise12.2950,000614,500716,352May 17 05:21 PM
POPS RICHARD FDirector and CEO, Alkermes plcMay 15Sale46.3850,0002,319,100666,352May 17 05:21 PM
POPS RICHARD FDirector and CEO, Alkermes plcMay 08Option Exercise12.2950,000614,500716,352May 10 06:05 PM
POPS RICHARD FDirector and CEO, Alkermes plcMay 08Sale44.3250,0002,215,775666,352May 10 06:05 PM
POPS RICHARD FDirector and CEO, Alkermes plcMay 01Option Exercise12.2950,000614,500716,352May 03 05:13 PM
MITCHELL PAUL JDirectorMay 01Option Exercise8.981,0008,9801,000May 03 05:34 PM
MITCHELL PAUL JDirectorMay 01Sale44.321,00044,3200May 03 05:34 PM
POPS RICHARD FDirector and CEO, Alkermes plcMay 01Sale44.0250,0002,201,167666,352May 03 05:13 PM
MITCHELL PAUL JDirectorApr 02Option Exercise8.981,0008,9801,000Apr 04 06:41 PM
MITCHELL PAUL JDirectorApr 02Sale46.751,00046,7500Apr 04 06:41 PM
Stejbach MarkSVP/Chief Comm Off, Alks IncMar 03Option Exercise0.002,813052,316Mar 05 06:33 PM
POPS RICHARD FDirector and CEO, Alkermes plcMar 03Option Exercise0.0013,0000672,131Mar 05 06:27 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.Mar 03Option Exercise0.002,8130173,598Mar 05 06:16 PM
Gaffin David JosephSVP, CLO, Alkermes, Inc.Mar 03Option Exercise0.001,250036,732Mar 05 06:09 PM
FRATES JAMES MSVP, Alks Inc; CFO ALKSMar 03Option Exercise0.002,813085,369Mar 05 06:02 PM
Cooke ShanePresident, Alkermes plcMar 03Option Exercise0.005,250087,602Mar 05 05:55 PM
BIBERSTEIN KATHRYN LEVP/CAO/CCO/CRO Alks Inc;Mar 03Option Exercise0.003,500041,756Mar 05 05:46 PM
Brown Iain MichaelSVP Finance & CAO, Alks Inc.Mar 03Option Exercise0.001,250022,264Mar 05 05:35 PM
MITCHELL PAUL JDirectorMar 01Option Exercise11.441,00011,4409,000Mar 05 05:05 PM
Stejbach MarkSVP/Chief Comm Off, Alks IncMar 01Option Exercise0.005,250051,837Mar 05 06:33 PM
POPS RICHARD FDirector and CEO, Alkermes plcMar 01Option Exercise0.0017,5000666,910Mar 05 06:27 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.Mar 01Option Exercise0.004,5000172,111Mar 05 06:16 PM
Gaffin David JosephSVP, CLO, Alkermes, Inc.Mar 01Option Exercise0.002,250036,145Mar 05 06:09 PM
FRATES JAMES MSVP, Alks Inc; CFO ALKSMar 01Option Exercise0.004,500083,882Mar 05 06:02 PM
Cooke ShanePresident, Alkermes plcMar 01Option Exercise0.007,000085,992Mar 05 05:55 PM
BIBERSTEIN KATHRYN LEVP/CAO/CCO/CRO Alks Inc;Mar 01Option Exercise0.005,750040,463Mar 05 05:46 PM
Brown Iain MichaelSVP Finance & CAO, Alks Inc.Mar 01Option Exercise0.002,250021,677Mar 05 05:35 PM
MITCHELL PAUL JDirectorMar 01Sale57.041,00057,0408,000Mar 05 05:05 PM
Stejbach MarkSVP/Chief Comm Off, Alks IncFeb 26Option Exercise0.002,625047,754Feb 28 06:46 PM
POPS RICHARD FDirector and CEO, Alkermes plcFeb 26Option Exercise0.0010,0000653,855Feb 28 06:42 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.Feb 26Option Exercise0.002,6250168,385Feb 28 06:37 PM
Gaffin David JosephSVP, CLO, Alkermes, Inc.Feb 26Option Exercise0.001,100034,219Feb 28 06:30 PM
FRATES JAMES MSVP, Alks Inc; CFO ALKSFeb 26Option Exercise0.002,625080,156Feb 28 06:18 PM
Brown Iain MichaelSVP Finance & CAO, Alks Inc.Feb 26Option Exercise0.001,100019,751Feb 28 05:49 PM
Cooke ShanePresident, Alkermes plcFeb 26Option Exercise0.004,425081,293Feb 28 05:54 PM
BIBERSTEIN KATHRYN LEVP/CAO/CCO/CRO Alks Inc;Feb 26Option Exercise0.003,750035,818Feb 28 05:40 PM
BIBERSTEIN KATHRYN LEVP/CAO/CCO/CRO Alks Inc;Feb 20Option Exercise17.9917,242310,18432,068Feb 21 05:37 PM
POPS RICHARD FDirector and CEO, Alkermes plcFeb 17Option Exercise0.008,7500646,436Feb 21 06:07 PM
Stejbach MarkSVP/Chief Comm Off, Alks IncFeb 17Option Exercise0.003,000047,013Feb 21 06:10 PM
LANDINE MICHAEL JSVP, Corp Dev., Alkermes, Inc.Feb 17Option Exercise0.003,0000166,693Feb 21 06:01 PM
FRATES JAMES MSVP, Alks Inc; CFO ALKSFeb 17Option Exercise0.003,0000147,039Feb 21 05:55 PM
Gaffin David JosephSVP, CLO, Alkermes, Inc.Feb 17Option Exercise0.002,500033,907Feb 21 06:00 PM
Cooke ShanePresident, Alkermes plcFeb 17Option Exercise0.004,500079,208Feb 21 05:51 PM
Brown Iain MichaelSVP Finance & CAO, Alks Inc.Feb 17Option Exercise0.002,500019,443Feb 21 05:44 PM
BIBERSTEIN KATHRYN LEVP/CAO/CCO/CRO Alks Inc;Feb 17Option Exercise0.003,750015,974Feb 21 05:37 PM
Stejbach MarkSVP/Chief Comm Off, Alks IncFeb 16Option Exercise17.3010,880188,22454,893Feb 21 06:10 PM
Stejbach MarkSVP/Chief Comm Off, Alks IncFeb 16Sale70.5010,880767,09244,013Feb 21 06:10 PM
Cooke ShanePresident, Alkermes plcFeb 02Option Exercise16.5572,7931,204,724147,501Feb 02 06:07 PM
Cooke ShanePresident, Alkermes plcFeb 02Sale60.5572,7934,407,67974,708Feb 02 06:07 PM
MITCHELL PAUL JDirectorFeb 01Option Exercise11.441,00011,4409,000Feb 02 06:04 PM
MITCHELL PAUL JDirectorFeb 01Sale56.771,00056,7708,000Feb 02 06:04 PM
Cooke ShanePresident, Alkermes plcJan 29Option Exercise16.553,30054,61578,008Jan 29 09:55 PM
Cooke ShanePresident, Alkermes plcJan 29Sale60.003,300198,00074,708Jan 29 09:55 PM
Cooke ShanePresident, Alkermes plcJan 26Option Exercise16.551,70028,13576,408Jan 29 09:55 PM
Cooke ShanePresident, Alkermes plcJan 26Sale60.021,700102,02874,708Jan 29 09:55 PM
Cooke ShanePresident, Alkermes plcJan 11Option Exercise16.556,207102,72680,915Jan 16 06:30 PM
Cooke ShanePresident, Alkermes plcJan 11Sale60.226,207373,80974,708Jan 16 06:30 PM
MITCHELL PAUL JDirectorJan 02Option Exercise11.441,00011,4409,000Jan 03 05:11 PM
MITCHELL PAUL JDirectorJan 02Sale54.991,00054,9908,000Jan 03 05:11 PM
Brown Iain MichaelSVP Finance & CAO, Alks Inc.Dec 29Sale54.8110,652583,88616,943Jan 02 06:28 PM
ANSTICE DAVID WDirectorDec 13Option Exercise11.4440,000457,60055,000Dec 14 05:26 PM
MITCHELL PAUL JDirectorDec 01Option Exercise11.441,00011,4409,000Dec 01 05:32 PM
MITCHELL PAUL JDirectorDec 01Sale51.981,00051,9808,000Dec 01 05:32 PM
FRATES JAMES MSVP, Alks Inc; CFO ALKSNov 29Option Exercise12.2920,932257,254164,971Nov 30 06:18 PM
FRATES JAMES MSVP, Alks Inc; CFO ALKSNov 29Sale50.5120,9321,057,249144,039Nov 30 06:18 PM